Side effects of Vidagliptin
Reading File
Searching the Web
vildagliptin side effects adverse reactions 2024
Finding Sources
Searching PubMed
vildagliptin adverse effects safety
Reading File
Reading File
Reading File
Reading File
Reading File
Here is a complete, well-organized breakdown of vildagliptin's side effects:
Vildagliptin (Galvus) - Side Effects
Vildagliptin is a DPP-4 inhibitor (gliptin) used for type 2 diabetes. It binds DPP-4 covalently, increasing active GLP-1 and GIP levels to lower blood glucose in a glucose-dependent manner.
Very Common (>1/10)
| Side Effect | Notes |
|---|---|
| Nasopharyngitis | Most consistently reported across all DPP-4 inhibitors; upper respiratory tract infection |
Common (1/100 to 1/10)
Neurological:
- Dizziness
- Headache
- Tremor
Gastrointestinal:
- Nausea
- Constipation
- Diarrhea
- Vomiting
- Gastroesophageal reflux disease (GERD)
- Abdominal pain (including upper abdominal pain)
Metabolic:
- Hypoglycemia - low risk as monotherapy; risk rises significantly when combined with a sulfonylurea or insulin
Other:
- Peripheral edema
- Blurred vision
Uncommon (1/1000 to 1/100)
- Flatulence
- Hypoglycemia (as monotherapy; upgraded to "common" when used with sulfonylrueas/insulin)
Rare but Serious
1. Hepatotoxicity
Rare cases of hepatic dysfunction including hepatitis have been reported. Elevations in ALT/AST (>=3x ULN) occurred in ~0.2-0.3% of patients. These are generally:
- Asymptomatic and reversible on discontinuation
- Non-progressive; not associated with cholestasis or jaundice
Important: Liver function tests (LFTs) should be checked quarterly during the first year of use and periodically thereafter. - Katzung's Basic and Clinical Pharmacology, 16th Ed
2. Bullous Pemphigoid (BP)
Vildagliptin has among the highest reported rates of drug-induced bullous pemphigoid of all gliptins. BP is an autoimmune blistering skin condition. Signs include tense blisters, urticarial plaques, and intense itching. Vildagliptin should be discontinued if BP develops. - Andrews' Diseases of the Skin
3. Pancreatitis
Acute pancreatitis has been reported with vildagliptin (and the gliptin class generally). A 2025 systematic review specifically reviewed gliptin-induced acute pancreatitis. Patients should be counseled to seek immediate care for severe, persistent abdominal pain.
4. Angioedema
Rare cases of angioedema have been reported. Risk is higher when vildagliptin is combined with an ACE inhibitor. Most cases are mild and resolve without stopping the drug.
5. Hypersensitivity Reactions
- Anaphylaxis
- Urticaria
- Bullous or exfoliative skin lesions (including Stevens-Johnson syndrome)
- Joint pain (arthralgia) - an FDA-issued class warning for all DPP-4 inhibitors; resolves on stopping the drug
6. Vasculitis
Medsafe (NZ) issued a safety signal in February 2022 regarding a possible risk of vasculitis with vildagliptin products (Galvus, Galvumet).
Special Situations
| Situation | Effect |
|---|---|
| + Sulfonylurea | Hypoglycemia becomes common; also tremor, dizziness, hyperhidrosis, asthenia |
| + Insulin | Hypoglycemia risk; headache, nausea, GERD, chills also reported |
| + ACE inhibitor | Higher rate of angioedema |
| Renal impairment | Requires dose reduction (unlike linagliptin); significant dose adjustment in CKD |
| Pregnancy | Avoid unless benefits clearly outweigh risks |
What Does NOT Happen
Unlike some other antidiabetic drugs:
- No weight gain - body weight is essentially neutral
- No CYP450 drug interactions - vildagliptin is not metabolized by CYP enzymes, giving it a low drug-drug interaction profile
- No cardiovascular harm - no increase in MACE events in trials (though a 2025 network meta-analysis, PMID 39639837 noted saxagliptin-specific heart failure risk; vildagliptin data is less comprehensive)
Sources: Katzung's Basic and Clinical Pharmacology 16th Ed; Goodman & Gilman's Pharmacological Basis of Therapeutics; Andrews' Diseases of the Skin; EU/Malta regulatory SmPC; Medsafe NZ
How does vildagliptin compare to other DPP-4 inhibitors for safety?
Finding Sources
Searching PubMed
"DPP-4 inhibitors" safety comparison network meta-analysis
Searching the Web
vildagliptin vs sitagliptin saxagliptin linagliptin safety comparison hepatotoxicity heart failure bullous pemphigoid
Finding Sources
Finding Sources
Searching PubMed
"dipeptidyl peptidase 4 inhibitors" cardiovascular heart failure pancreatitis
Reading File
Finding Sources
Reading Web Page
vildagliptin safety comparison hepatotoxicity heart failure bullous pemphigoid pancreatitis renal
Finding Sources
Searching PubMed
vildagliptin bullous pemphigoid DPP-4 inhibitor risk
I now have enough data for a thorough, well-sourced comparison. Here it is:
Vildagliptin vs. Other DPP-4 Inhibitors: Safety Comparison
The five main DPP-4 inhibitors are vildagliptin (EU), sitagliptin, saxagliptin, linagliptin, and alogliptin (last three available in the US). They share a common mechanism but have clinically important safety differences.
1. Hepatotoxicity - Vildagliptin-Specific Concern
| Drug | Liver Risk | LFT Monitoring Needed? |
|---|---|---|
| Vildagliptin | Rare hepatic dysfunction/hepatitis reported | Yes - quarterly in year 1, then periodically |
| Sitagliptin | No consistent signal | No |
| Saxagliptin | No consistent signal | No |
| Linagliptin | No consistent signal | No |
| Alogliptin | Rare cases of hepatic failure reported; causality uncertain | Discontinue if liver failure occurs |
Vildagliptin is the only agent with a formal recommendation for quarterly LFT monitoring during the first year of use. Pooled trial data show the incidence of ALT/AST >=3x ULN was ~0.2-0.3%, which is not statistically higher than comparators (MHRR 1.19; 95% CI 0.79-1.81), but the regulatory requirement for monitoring stands due to spontaneous post-marketing hepatitis reports. - Katzung's Basic and Clinical Pharmacology 16th Ed; PMC5813467
2. Cardiovascular Safety - Saxagliptin Stands Out
| Drug | Heart Failure Risk | MACE |
|---|---|---|
| Vildagliptin | No increased risk (MHRR 1.08; 95% CI 0.68-1.70); VIVIDD trial confirms safety even in NYHA I-III CHF | Neutral |
| Sitagliptin | No increased risk (TECOS trial) | Neutral |
| Saxagliptin | Increased HF hospitalizations (HR 1.27; 95% CI 1.07-1.51; SAVOR-TIMI) - FDA/EMA warning; avoid in HF | Neutral for MACE |
| Linagliptin | No increased risk (CARMELINA trial) | Neutral |
| Alogliptin | Small signal toward increased HF (EXAMINE trial) | Neutral |
Vildagliptin compares favorably to saxagliptin here. Large cardiovascular outcome trials (CVOTs) have been completed for sitagliptin, saxagliptin, and alogliptin; vildagliptin lacks a dedicated large CVOT but meta-analysis data are reassuring. - Goodman & Gilman's; Goldman-Cecil Medicine
3. Bullous Pemphigoid (BP) - Vildagliptin Has the Highest Risk
| Drug | Adjusted Odds Ratio for BP |
|---|---|
| Vildagliptin | OR 10.4 (Finnish registry, 95% CI 4.56-23.80); OR 10.67 (Israeli data, 95% CI 5.09-22.36) |
| Linagliptin | OR 6.65 (95% CI 2.24-19.72) |
| Sitagliptin | OR 1.37-2.13 (lower, less consistent) |
| Saxagliptin | OR 2.90 (95% CI 0.47-17.74) |
| Alogliptin | Limited data |
Vildagliptin carries a significantly higher BP risk than any other gliptin, with odds ratios up to 10-fold in large registry studies. It was the most commonly reported agent in EudraVigilance pharmacovigilance data. Vildagliptin-induced BP tends to occur in elderly patients and often presents with a non-inflammatory (low-eosinophil) phenotype. - Andrews' Diseases of the Skin; Frontiers in Immunology review
4. Pancreatitis - Class Effect, No Agent Stands Out
All DPP-4 inhibitors carry a class warning for pancreatitis. For vildagliptin specifically:
- Incidence was 0.3/100 SYEs - identical to comparators
- A meta-analysis of 69 trials found OR 0.97 (95% CI 0.37-2.53) - no increased risk vs. comparators
- Alogliptin had pancreatitis in 11/5902 patients (0.2%) vs 5/5183 (0.1%) for comparators in its CVOT
No individual gliptin is clearly safer or more dangerous for pancreatitis; the signal is a class effect. - Katzung's; PMC5813467
5. Renal Dosing - Linagliptin is Uniquely Safe
| Drug | Requires Renal Dose Adjustment? |
|---|---|
| Vildagliptin | Yes |
| Sitagliptin | Yes (reduce to 50 mg at GFR 30-50; 25 mg if <30) |
| Saxagliptin | Yes |
| Alogliptin | Yes (12.5 mg at GFR 30-60; 6.25 mg if <30) |
| Linagliptin | No - cleared hepatobiliarily; safe in all CKD stages including dialysis |
For patients with chronic kidney disease, linagliptin is the preferred DPP-4 inhibitor. Vildagliptin is among those requiring dose reduction. - Brenner & Rector's The Kidney; Lippincott Pharmacology
6. Drug Interactions - Saxagliptin Most Problematic
| Drug | CYP Metabolism | Key Interaction Risk |
|---|---|---|
| Vildagliptin | Not CYP-metabolized | Low interaction risk |
| Sitagliptin | Minimal (CYP3A4, CYP2C9) | Low |
| Saxagliptin | CYP3A4/5 | Dose must be halved with strong CYP3A4 inhibitors (ketoconazole, ritonavir, etc.) |
| Linagliptin | Not CYP (enterohepatic) | Low |
| Alogliptin | Minimal | Low |
Vildagliptin and linagliptin have the cleanest drug interaction profiles. - Goodman & Gilman's
7. Shared Class Effects (All Agents)
- Upper respiratory tract infection / nasopharyngitis (very common)
- Headache
- Weight neutrality
- Low intrinsic hypoglycemia risk (all agents)
- Severe joint pain / arthralgia (FDA class warning)
- Hypersensitivity reactions including angioedema, urticaria, Stevens-Johnson syndrome
Summary Table
| Safety Domain | Best Option | Worst / Most Caution |
|---|---|---|
| Liver (hepatotoxicity) | Sitagliptin, saxagliptin, linagliptin | Vildagliptin (monitoring required) |
| Heart failure | Vildagliptin, sitagliptin, linagliptin | Saxagliptin (avoid in HF) |
| Bullous pemphigoid | Sitagliptin (lowest OR) | Vildagliptin (highest OR ~10x) |
| Pancreatitis | No difference - class effect | All equal |
| Renal impairment | Linagliptin (no adjustment needed) | All others require dose reduction |
| Drug interactions | Vildagliptin, linagliptin | Saxagliptin (CYP3A4-dependent) |
Bottom line: Vildagliptin is broadly safe with a neutral cardiac and pancreatic profile, but stands out for its hepatotoxicity monitoring requirement and the highest bullous pemphigoid risk in the class. Saxagliptin is the agent most restricted by cardiovascular concerns. Linagliptin has the most favorable renal and drug-interaction profile.
Sources: Katzung's Basic and Clinical Pharmacology 16th Ed; Goodman & Gilman's Pharmacological Basis of Therapeutics; Lippincott Pharmacology; Andrews' Diseases of the Skin; Brenner & Rector's The Kidney; PMC5813467 (vildagliptin clinical safety review)
This is a shared conversation. Sign in to Orris to start your own chat.